From Petroleum to Pharmaceuticals: Exploring the UAE's Key Strategic Shift Towards Economic Diversification

The United Arab Emirates (UAE) government has been actively pursuing economic diversification in recent years, aiming to reduce its reliance on oil and natural gas. According to data from the Ministry of Economy's Investment Office, the UAE has successfully lowered the contribution of oil and gas output to less than 40% of its Gross Domestic Product (GDP). Under the Dubai Industrial Strategy 2030, the government has identified pharmaceuticals and medical devices as one of the six key industries to promote, envisioning Dubai as a global hub for operations, production, and distribution in this sector. 

UAE’s Pharmaceutical Industry to Reach Nearly $5 Billion Next Year; Incentives Attract Global Enterprises

Over the past decade, the UAE’s pharmaceutical sector has experienced remarkable growth, with the number of production facilities increasing nearly sixfold between 2010 and 2021. This reflects the country’s strategic focus on enhancing pharmaceutical manufacturing capabilities. The market value of the pharmaceutical industry has grown from $1.5 billion in 2011 to approximately $3.7 billion in 2021, with projections to reach $4.7 billion by 2025. 

Currently, the UAE is capable of producing over 2,500 types of medications, meeting domestic demand while also supplying international markets. To further boost the pharmaceutical industry, the UAE government has implemented several incentives, such as exempting companies from corporate and income taxes, to attract multinational pharmaceutical and medical device companies to establish regional headquarters or production bases in the country. Additionally, substantial investments in advanced healthcare facilities and research and development (R&D) aim to drive innovation and foster international collaborations, injecting new momentum into the sector. 

Expanding Across the Middle East and Africa; Julphar Explores Biotechnology Partnerships in Taiwan

In addition to offering generous incentives, the UAE is actively collaborating with global pharmaceutical companies to enhance local production capabilities. For instance, Gulf Pharmaceutical Industries (Julphar) partnered with China’s East Sunshine Pharmaceuticals to pioneer the production of modern insulin analogs in the Middle East, addressing the region's growing diabetes challenges. 

A subsidiary of Julphar, Planet Pharmacies LLC, stands as one of the largest pharmaceutical suppliers in the Middle East and Africa, operating over 270 retail pharmacies and wholesale distributors while serving more than 2,100 clients. As a leading global insulin manufacturer, Planet Pharmacies LLC will participate in the upcoming Taiwan Healthcare+ Expo this December. Their goal is to seek partnerships in biotechnology, regenerative medicine, and precision diagnostics. The company is particularly interested in collaborating with firms that have established products or market experience to further expand its footprint across the Middle East and Africa. 

Promising Prospects for UAE’s Pharmaceutical Sector 

As the UAE’s pharmaceutical industry undergoes rapid expansion, supported by government policies and international partnerships, the nation is steadily advancing toward its goal of becoming a global pharmaceutical hub. With substantial market potential and a commitment to technological innovation, the UAE continues to capture the attention of pharmaceutical enterprises worldwide. 

● Also Want to Explore More Business Opportunities?
【Register for the 2024 Heathcare+ Expo Now to find the best partners! ▸】